Jason_LSE

Consultant, Engineer--Investor, Educator

    • Jason_LSEJason_LSE
      ·02-22
      $PDYN 20260220 6.0 PUT$ Sharing my personal views of PDYN potential.  The collaboration between Palladyne AI Corp. (PDYN), (RCAT) and (PLTR) focuses on integrating advanced, AI-driven, autonomous software into specialized, military-grade, and commercial drones. Their partnership is aimed at enhancing the operational efficiency of unmanned systems for defense and, potentially, civil customers. Key Collaborations (PDYN with RCAT, PLTR & DPRO) Integration of "Palladyne Pilot" AI: The core of the collaboration is integrating "Palladyne Pilot" software into RCATs Teal Drones, including the "Teal 2"
      42Comment
      Report
    • Jason_LSEJason_LSE
      ·02-20
      $RCAT 20260213 16.0 CALL$ Rcat is growing its awareness in the Indo-Pacific region at the recent Singapore Air + Marine Show.  At the Singapore Airshow 2026, Red Cat Holdings (RCat) showcased its pivot toward a multi-domain, unmanned systems provider with key exhibits and announcements focused on maritime and aerial intelligence, surveillance, and reconnaissance (ISR). Key highlights from Red Cat at the Singapore Airshow 2026 included: V7 Uncrewed Surface Vessel (USV): Red Cat unveiled the V7 "strike boat," designed by its subsidiary Blue Ops for maritime autonomy, deep-strike missions, and anti-ship engagements. The V7 is capable of carrying explosive ordnance, tactical missiles, and aerial drones, marking Red Cat's exp
      116Comment
      Report
    • Jason_LSEJason_LSE
      ·02-18
      $Hims & Hers Health Inc.(HIMS)$ Just sharing my opinion. The latest dip begun to look attractive. [Smile]   Hims & Hers Health (HIMS) stock has fallen to the $16 range primarily due to intense legal and regulatory pressure surrounding its compounded GLP-1 weight-loss products, compounded by a lawsuit from Novo Nordisk and fears of lost market share. Here are the specific reasons for the decline: Lawsuit and Regulatory Pressure: In early February 2026, Novo Nordisk filed a lawsuit against Hims & Hers to permanently ban the company from selling compounded versions of its drugs (such as Ozempic and Wegovy). This followed a direct warning from the FDA regarding "illegal copycat drugs". Withdrawal of Copycat Product
      2.26K1
      Report
    • Jason_LSEJason_LSE
      ·02-14
      $USA Rare Earth Inc.(USAR)$ Continue bullish on rare earth stocks. Waiting for dip opportunities. 
      3.07K8
      Report
    • Jason_LSEJason_LSE
      ·02-10
      $BMNR 20260206 18.0 PUT$ One small bite at a time, building up my appetite as it hover 😋 . Preparing for a big momentum..lor.
      584Comment
      Report
    • Jason_LSEJason_LSE
      ·02-07
      To me, even receiving a simple "Like" is an Encouragement. [Smile]  Let's support each other, so as to encourge a more lively community chat grp. Thks so much, everybody. [Heart]  
      326Comment
      Report
    • Jason_LSEJason_LSE
      ·02-07
      🤑🍻🥂
      441Comment
      Report
    • Jason_LSEJason_LSE
      ·02-07
      An inspiring experience. Hope to share more 🙏
      258Comment
      Report
    • Jason_LSEJason_LSE
      ·02-04
      $BMNR 20260123 27.5 PUT$ I still have faith & conviction and will DCA to accumulate as it dip.  Sharing the "+and- ve" summary of BMNR recent AGM:-- BitMine Immersion Technologies (BMNR) is making a bold move into the crypto space, pivoting into a "digital Berkshire-style" capital allocator with a heavy emphasis on Ethereum (ETH) and "moonshot" investments. The company's annual general meeting (AGM) in Las Vegas on January 15, 2026, was a pivotal moment, showcasing their aggressive strategy to become a premier ETH treasury company. The 4 Pillars of Growth:-- Maximizing Treasury Yield: Utilizing strategies like MAVAN (Made-in-America Validator Network) for Ethereum staking. Strategic "Moonshots": Including a $200
      1.95K7
      Report
    • Jason_LSEJason_LSE
      ·01-29
      $BitMine Immersion Technologies Inc.(BMNR)$ DCA with conviction in BMNR. I am an engineer-investor, can appreciate & align with their new hired CFO/COO (Young Kim).  Will share some of my research next, as I build up the case.😉
      2.56K4
      Report
     
     
     
     

    Most Discussed